In blocking studies for MKN-45 xenografts, tumor uptake of 89Zr- df-onartuzumab decreased approximately 3.8-fold by plus of 10 nmol of unlabeled onartuzumab, suggesting that competitive blocking by unlabeled onartuzumab occurred in the tumor.
For chemical signal blocking study, the HMEEC-1 cells were cultured for 2 days to 80% confluence.
For the blocking study, cells were incubated with the hybrid probe in the presence of RGD2 (10 μM) at 37 °C for 21 h and then treated as described above.
The fluorescence intensity of the cells was represented as a ratio to the dosage as follows: For the blocking study, C6 cells were treated with type I collagen (Col I; 100 μg/1 mL DMEM) for 24 h at 37°C.
Statistical difference for the blocking study was tested by unpaired Student's t test and was considered significant for P < 0.05.
For the blocking study, a SD rat (n = 3, male, 260 to 280 g; 8 weeks old) was injected with unlabeled MMPIP (1 mg/kg) 30 s prior to the injection of [11C]MMPIP (51 ± 5 MBq, 0.5 nmol).
For blocking studies, both the lower well containing CCL21 (100 ng/ml) and the upper well containing the DCs were pre-treated with 10 µg/ml galactose or α2,8-linked polysialic acid coupled to Polyacrylamide (Lectinity) for 45 min. at 37°C before performing the migration assay.
A similar protocol was followed for the RGD-peptide blocking study.
For blocking studies, the animals were pre-dosed with 300 μg of DCFPyL in 50 μL saline about 10 min prior to radiotracer injection.
For blocking studies, the above-mentioned DU-145 tumor-bearing mice were intravenously administered with 100 μL of -125I]IV-OH (37 kBq) mixed with an excess of each unlabeled sigma ligand, haloperidol (10 μmol/kg), SA4503 (10 μmol/kg) [28], or -p IV (10 μmol/kg).
